Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21310800 | 0.86 | EGFR (0.51) | EGFRTLR9TLR8TLR7CNR2 | |
| SCHEMBL21311035 | 0.82 | EGFR (0.52) | EGFRTLR9TLR8TLR7CNR2 | |
| SCHEMBL21310985 | 0.81 | EGFR (0.42) | EGFRTLR9TLR8TLR7CNR2 | |
| SCHEMBL21311020 | 0.79 | EGFR (0.44) | EGFRTLR9TLR8TLR7 | |
| SCHEMBL21310817 | 0.79 | EGFR (0.56) | EGFRCNR2 | |
| SCHEMBL21310754 | 0.77 | EGFR (0.48) | EGFRTLR9TLR8TLR7CNR2 | |
| SCHEMBL21310756 | 0.76 | PDE4B (0.49) | EGFRCNR2 | |
| SCHEMBL21310986 | 0.76 | EGFR (0.55) | EGFRTLR7CNR2 | |
| SCHEMBL21311048 | 0.73 | CCR5 (0.39) | TLR9TLR8TLR7 | |
| SCHEMBL6270717 | 0.72 | ALDH1A1 (0.61) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174245-B2 | Benzimidazole compounds and derivatives as EGFR inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-16 | — | — | US | disclosed |
| US-20200377476-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-03 | — | — | US | disclosed |
| WO-2019162323-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377476-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | EGFR 1/4885HRH1 458/4885TLR9 3459/4885 |
| US-11174245-B2 | Benzimidazole compounds and derivatives as EGFR inhibitors | EGFR, ERBB2, ERBB3 | EGFR 1/4885HRH1 384/4885TLR9 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.